Skip to main content
FDA has approved a ustekinumab biosimilar (ustekinumab-aekn; AKA Selardsi), made by Teva & Alvotech, for the treatm

Dr. John Cush RheumNow

2 years 5 months ago
FDA has approved a ustekinumab biosimilar (ustekinumab-aekn; AKA Selardsi), made by Teva & Alvotech, for the treatment of moderate to severe plaque psoriasis (PsO) and active psoriatic arthritis (PsA) in both adults and pediatric pts.https://t.co/ZXvFjjH7Qt https://t.co/7FJKxSVAgL
The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at the Consortium’s first anniversary meeting an expanded partnership with the U.S. Food and Drug Administration (FDA) with the inclusion of the Center for Biologics Evaluation and Research (CBER).
#RNL2024 @philseo: I now give Tociliizumab for nearly all patients with GCA
GiACTA shows we weren't doing well enough

Dr. John Cush RheumNow

2 years 5 months ago
#RNL2024 @philseo: I now give Tociliizumab for nearly all patients with GCA GiACTA shows we weren't doing well enough w/steroid monotherapy GiACTA shows dosing frequency does not make big diff in new diagnosis, but makes a diff in relapsing disease https://t.co/khJe0bwKXy
GCA pts on Toci mgmt
#RNL2024 @RheumNow
@philseo rec's increase interval to q4w before d/c TCZ
Limited evidence from th

Dr. John Cush RheumNow

2 years 5 months ago
GCA pts on Toci mgmt #RNL2024 @RheumNow @philseo rec's increase interval to q4w before d/c TCZ Limited evidence from this from study of 17 patients where weaned off TCZ. Hopes to capture pts with mild flares with tapering dose. MAGICA trial will study abrupt d/c v wean dose
Burnout or Retire

Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv. Is

Dr. John Cush RheumNow

2 years 6 months ago
Burnout or Retire Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv. Is it time to worry about burnout and those who are leaving healthcare? https://t.co/p8ek7A8HAk https://t.co/nH5fDywLic
PNAS: Autoimmunity against MDA5 induces fibrotic ILD in mice. In this murine model of dermatomyositis, treatment with e

Dr. John Cush RheumNow

2 years 6 months ago
PNAS: Autoimmunity against MDA5 induces fibrotic ILD in mice. In this murine model of dermatomyositis, treatment with either anti-CD4 or anti-IL-6 receptor antibody ameliorated the MDA5-induced fibrotic ILD. https://t.co/CahyGfTn4g https://t.co/lfpdgEvGmx
Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations. 
ILD Onset in MDA-5 Dermatomyositis

MDA5 antibody-positive DM is a rare, aggressive and progressive subtype of DM. Its'

Dr. John Cush RheumNow

2 years 6 months ago
ILD Onset in MDA-5 Dermatomyositis MDA5 antibody-positive DM is a rare, aggressive and progressive subtype of DM. Its' severity is dependent on the development of progressive ILD, manifesting as either RPILD and CILD. https://t.co/08wAYj06DH https://t.co/TQWHGR27O9
World Congress on OP, OA & MSK Disorders

Bone and musculoskeletal disease researchers and physicians from around th

Dr. John Cush RheumNow

2 years 6 months ago
World Congress on OP, OA & MSK Disorders Bone and musculoskeletal disease researchers and physicians from around the world will meet today in London for the opening of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. https://t.co/kzvWD4Rmki https://t.co/PJQREsJO9v
Neuropsychiatric SLE - 2/3 Improved at 12 Months

The management and outcomes of neuropsychiatric systemic lupus erythe

Dr. John Cush RheumNow

2 years 6 months ago
Neuropsychiatric SLE - 2/3 Improved at 12 Months The management and outcomes of neuropsychiatric systemic lupus erythematosus (NPSLE) can be challenging as there is limited data. https://t.co/p0GEtkUTdt https://t.co/EZhjH6PxWQ
TNFi mAbs, JAKi, –IL-17 are protective against Anterior Uveitis (AU) in AxSpA. Metanalysis of 44 RCTs shows AU IR:
-

Dr. John Cush RheumNow

2 years 6 months ago
TNFi mAbs, JAKi, –IL-17 are protective against Anterior Uveitis (AU) in AxSpA. Metanalysis of 44 RCTs shows AU IR: - TNF mAbs: 4.1 - etanercept 5.4 - IL-17i: 2.8 - JAKi: 1.5 - placebo: 10.8 https://t.co/sxqCXkD0up https://t.co/XWXUPmCtZr
Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks. They gave us what we really want from these talks – personal opinions and approaches that go beyond the guidelines. They really dropped a selection of pearls on us and I wanted to share a few of these with you.
A prospective study from the Netherlands analyzed the comparative value of simultaneous labial and parotid salivary gland biopsies performed in patients with sicca complaints and suspected Sjogren's syndrome (SjD).
Of 375 #Gout pts D/C pegloticase after a median of 8 infusions (taken 112days (max 1,240d). Only 73% had SUA < 6

Dr. John Cush RheumNow

2 years 6 months ago
Of 375 #Gout pts D/C pegloticase after a median of 8 infusions (taken 112days (max 1,240d). Only 73% had SUA < 6 during pegloticase. After D/C 84% went on ULT (63% allopurinol; 34% febuxostat; after mean 92d); after ≥ 30 days), 51% achieved SUA < 6 https://t.co/unkvt1whrs https://t.co/DgVpBgKXcm
×